Q4 2024 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Key Points
- Genomma Lab Internacional SAB de CV (GNMLF) reported a strong Q4 and full-year 2024 with net sales growing 32.4% in Q4 and 13% for the full year.
- The company achieved significant profitability gains with EBITDA growing 55% in Q4 and 26% for the full year, driven by productivity initiatives and manufacturing efficiencies.
- Net income increased by 97% for the full year, resulting in EPS doubling in 2024, marking a significant milestone in financial performance.
- Cash flow generation hit a record high of MXN2.8 billion, representing a 36% increase, with 68% of sales maintaining or gaining market share.
- The company maintained a strong balance sheet with a leverage ratio of less than 1 times net debt to EBITDA, providing increased capital allocation flexibility.
- The cash conversion cycle reached 110 days, temporarily impacted by Suerox inventory buildup amid capacity constraints.
- The company faced headwinds in Peru and Chile, despite strong performance in other Latin American markets.
- There is uncertainty regarding the ability to repatriate cash from Argentina due to local economic conditions.
- The company is cautious about providing specific growth guidance for 2025 and 2026, indicating potential uncertainty in future revenue projections.
- Despite strong financial performance, the company is not planning significant CapEx, which may limit future expansion opportunities.
Greetings, ladies and gentlemen. Thank you for joining Genomma Lab's fourth quarter 2024 earnings conference call.
(Operator Instructions)
As a reminder, this meeting is being recorded and will be available for replay on the investor relations section of Genomma's website following the call.
I'll now turn the call over to Christianne Ibanez, Genomma's head of investor relations. Please go ahead.
Thank you and welcome, everyone. On today's call are Marco Sparvieri, Chief Executive Officer, and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements such as the company's financial guidance and expectations including long-term objectives and forecasts as well as expectations regarding Genomma's business, assets, products, strategies, demand, and markets.
These statements are subject to risks and uncertainties that could cause actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
